Septerna Shares Rise 29% on First Trading Day
Septerna stock has risen 29%, to $23.31, since it debuted on the exchange Friday. The San Francisco biotechnology company said Thursday it would sell 16 million shares at $18 apiece, giving the company a projected market capitalization of $288 million.
Septerna is seeking a valuation of $743.1 million in its upsized U.S. initial public offering, the Goldman Sachs-backed drug ...
Septerna upped the size of its offering twice before pricing a stock sale that raised funds for its lead candidate, a ...
Three sizable IPOs priced this past week, joined by a flurry of small issuers and blank check companies - Ingram Micro, ...
Septerna may be yet to disclose “any meaningful clinical data,” but the biotech clearly thinks there will be investor ...
Septerna Inc. shares soared as much as 42% in their trading debut after the biotechnology company raised $288 million in an ...
Septerna (SEPN), which is developing a treatment for hypoparathyroidism, has proposed terms for an upsized $175M initial ...
The gross proceeds from the offering are expected to be $288.0 million, before deducting underwriting discounts and commissions and other offering expenses. The offering is expected to close on ...
(Reuters) -Goldman Sachs-backed drug developer Septerna said on Thursday it was seeking a valuation of $743.1 million in its ...
Recent developments in healthcare cover a broad spectrum of issues: an analysis reveals that weight-loss drugs like Wegovy do ...
Septerna CEO Jeffrey Finer rang the opening bell on the Nasd | South San Francisco-based Septerna has scored with an upsized ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback